The decade-long Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study wrapped up this month. According to top-line results announced March 8 by Eli Lilly, more than four years of ...
Preliminary results from a landmark clinical trial to prevent Alzheimer’s disease (AD) symptoms show that an investigational anti-amyloid drug, solanezumab, did not demonstrate a statistically ...
INDIANAPOLIS -- Eli Lilly and Company (NYSE: LLY) today notified the University of California, San Diego (UCSD) of its intent to end its contract with the university for the management of the ...
Lilly remains committed to fighting Alzheimer's disease, with plaque-clearing mechanisms such as donanemab and remternetug, both in ongoing Phase 3 trials INDIANAPOLIS, March 8, 2023 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results